Endocrine Abstracts

Acromegaly represents a rare chronic disease mainly caused by GH pituitary adenoma with increased levels of GH and IGF-I. Diabetes mellitus was shown to increase cardiovascular morbidity and mortality in patients with acromegaly. Management of diabetes in acromegaly represents a challenging matter and deserves special considerations due to multiple factors that might be implicated in hyperglycemia including: i) the etiology of diabetes, which could be related to acromegaly per...

Primary hyperparathyroidism (PHPT) during pregnancy is an uncommon condition that may have consequences for either mother, offspring, or both. Treatment can be either surgical or conservative.The study aims: To compare maternal and fetal adverse outcomes between surgically (operated group) vs conservatively (non-operated group) treated mothers with gestational PHPT and to investigate the correlation between serum calcium and PTH values with complication ...

Management of type 2 diabetes (T2DM) has advanced since introducing sodium-glucose co-transporter 2 inhibitors (SGLT2i) with their protective cardiovascular and renal effects. However, in acromegaly patients with diabetes, the SGLT2i class is less attractive among endocrinologists because of the increased risk of diabetic ketoacidosis (DKA), and the use of incretin-based therapy as second-line treatment after metformin is more considered. This review aims to discuss the role o...

Context: Diabetes mellitus represents one of the most frequent metabolic comorbidities and occurs in 30% to 40% of patients with acromegaly. Patients with acromegaly develop insulin resistance due to GH excess, and in those with longstanding disease, insulin deficiency may occur. Moreover, the use of second-generation somatostatin receptor ligands (SRLs) pasireotide might contribute to the increased development in new-onset diabetes and the worsening of hyperglycemia. Manageme...

Introduction: Acromegaly is a chronic disease generally caused by a GH-secreting pituitary adenoma. GH excess causes insulin resistance and impair β cell function, predisposing patients with acromegaly to develop DM. Treatment of diabetes has been revolutionized since the introduction of sodium-glucose cotransporter inhibitors (SGLT2i). This novel class is widely used in type 2 diabetes mellitus (T2DM) and recently was approved for patients with heart failure with reduced...